DDrare: Database of Drug Development for Rare Diseases

17. 多系統萎縮症
［臨床試験数：107，薬物数：153（DrugBank：48），標的遺伝子数：59，標的パスウェイ数：104］

Searched query = "Multiple system atrophy", "MSA-C", "MSA-P", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 1) Inosine 5'-monophosphate; 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one; 11C-methylreboxetine; 13N-Ammonia; 18F-Dopa; 18F-Dopamne; AFFITOPE® PD01A + Adjuvant; AFFITOPE® PD03A + Adjuvant; AZD3241; AZD3241 100mg; AZD3241 300mg; AZILECT; AZILECT 1 mg comprimidos; Adjuvant without active component; Ammonia; Ampreloxetine; Ampreloxetine chydrochloride; Ampreloxetine hydrochloride; Angiotensin; Angiotensin-(1-7); Anti-Parkinson medication; Atomexetine; Autologous mesenchymal stem cells; Azilect; BHV-3241; BHV-4157; BIIB101; BOTULINUM TOXIN TYPE A; BQ123; Behavioral: BCI-FIT active querying; Behavioral: BCI-FIT adaptive signal modeling; Behavioral: BCI-FIT language modeling; Behavioral: BCI-FIT multi-modal access; Behavioral: Clinical characteristics of AMS patients; Behavioral: Conservative Measures for Orthostatic Hypotension; Behavioral: MOntreal Cognitive Assessment (MoCA); Blood sampling; Botulinum toxin type A; Bq123; Bydureon; CS10BR05; Captopril; Carbidopa; Carbidopa 200mg oral dose; Carbonate; DMI; DOPS; DaTSCAN™ Ioflupane (123I) Injection; DaTscan; Datscan; Desipramine; Desipramine (DMI); Device: Abdominal compression; Device: Deep Brain Stimulation; Device: sham compression; Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: [18F]-RO6958948; Domperidone; Droxidopa; EGCG; EGCG as putative neuroprotective agent; Emeramide; Entacapone; Entacapone 400mg oral dose; Exenatide; Exenatide Pen Injector [Bydureon]; FLUOXETINE; Fipamezole; Fipamezole hydrochloride; Fipamezole hydrochloride 30 mg oral disintegrating tablets; Fipamezole hydrochloride 60 mg oral disintegrating tablets; Fipamezole hydrochloride 90 mg oral disintegrating tablets; Fludrocortisone; Flumazenil; Fluoxetine; Fluoxétine; Flutemetamol; Flutemetamol F18; GREEN TEA LEAF; Gold; Green Tea; Green tea leaf; Homeostasis Model Assessment of insulin resistance (HOMA); Hydrogen; IUPAC name: 1-(2-Isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one; IVIg; Inosine; Intranasal Insulin; Intravenous immunoglobulin (IVIg); Intravesical injection of Botulinum A toxin; JP-1730/F01; JP-1730/F02; JP-1730/F03; L-Threo DOPS; LITHIUM CARBONATE; LITIO CARBONATO; Levodopa; Levodopa test; Lithium Carbonate; Lithium carbonate; Losartan; Metoprolol; Metoprolol tartrate 50 mg; Midodrine; Modal; N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE; NBMI; NT 101; Nebivolol; Nebivolol 5 mg; Nitrogen; Normal saline; Other: Abdominal compression; Other: Brain MRI (magnetic resonance imaging); Other: Sham abdominal compression; PROZAC; Procedure: Brain Magnetic Resonance Imaging (MRI); Procedure: determination of objective and subjective pain threshold; Pseudoephedrine; Pseudoephedrine + 480 ml water; Pseudoephedrine + 50 ml water; RASAGILINA MESILATO; Raclopride; Radiation: H215O PET; Radiation: PET (Positron Emission Tomography) Study; Rasagilina; Rasagiline; Rasagiline mesylate; Rifampicin; Riluzole; Rituximab; SAFINAMIDE; Safinamide; Safinamide Methanesulfonate; Safinamide methanesulfonate; Saline; Sildenafil25 mg; Sirolimus; Sirolimus 2 MG; Sunphenon EGCg; TD-9855; Tea leaf; Tllsh2910; Trimethaphan; Ubiquinol; Verdiperstat; Water; Xadago; Xeomin; [18F]FDOPA; [F-18]PBR06

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000036952	2019/06/04	04/06/2019	A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.	A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. - A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.	Patients who are suspected Parkinson's disease or related disorders, including dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobe degeneration, vascular parkinsonism, drug-induced parkinsonism, normal pressure hydrocephalus, and others.	18F-FDOPA, 11C-Raclopride PET	Nagoya City Rehabilitation Agency	NULL	Recruiting	20years-old	Not applicable	Male and Female	150	Not applicable	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

JPRN-UMIN000036952

2019/06/04

04/06/2019

A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.

A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients. - A PET study with 18F-FDOPA and 11C-Raclopride on Parkinson's disease and related disorders patients.

Patients who are suspected Parkinson's disease or related disorders, including dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal lobe degeneration, vascular parkinsonism, drug-induced parkinsonism, normal pressure hydrocephalus, and others.

18F-FDOPA, 11C-Raclopride PET

Nagoya City Rehabilitation Agency

NULL

Recruiting

20years-old

Not applicable

Male and Female

150

Not applicable

Japan